-
Lilly ceases clinical research of pomaglumetad methionil as schizophrenia treatment
INDIANAPOLIS — Eli Lilly has ceased ongoing clinical studies of an investigational treatment for schizophrenia.
The drug maker said that after recently conducting an independent futility analysis, it concluded that the second of Lilly's two pivotal studies "was unlikely to be positive in its primary efficacy endpoint if enrolled to completion." Additionally, the recently completed phase-2 study, which investigated pomaglumetad methionil (also known as mGlu2/3) as an adjunctive treatment with atypical antipsychotics, did not meet its primary endpoint.
-
Abbott's Humira gets support for expanded use
WASHINGTON — A panel of outside advisers to the Food and Drug Administration has backed wider use for Abbott Labs’ rheumatoid arthritis drug, Humira, for treating a type of inflammatory bowel disease.
According to published reports, the panel voted 15-2 that the benefits of Humira outweighed the risks in treating ulcerative colitis. However, the panel asked Abbott to conduct more studies upon Humira's approval.